Neurology Associates, PA

Maitland, Florida 32751-4723

7 studies enrolling now · 52 studies all time

What they study most

Agitation Associated With Alzheimer's Dementia, Alzheimer Disease, Autoimmune Diseases of the Nervous System, Brain Atrophy, Central Neuropathic Pain, Cerebrovascular Accident, Chronic Inflammatory Demyelinating Polyneuropathy, Cognition Disorders, Disease Progression, Early Parkinson Disease, Epilepsies, Partial, Epilepsy With Partial On-set Seizures

Studies at this site

• Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. — Recruiting now
• A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis — Recruiting now
• A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia — Recruiting now
• Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) — Recruiting now
• A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis — Recruiting now
• A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis — Recruiting now
• Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis — Recruiting now
• Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad) — Recruiting now
• A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple Sclerosis — Recruiting now
• A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS) — Running, not enrolling
• A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS) — Running, not enrolling
• A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis — Running, not enrolling
• A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis — Running, not enrolling
• Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) — Running, not enrolling
• A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis — Running, not enrolling
• A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation — Running, not enrolling
• Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS — Running, not enrolling
• Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab — Running, not enrolling
• An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab — Completed
• A Study to Assess Adults With CIDP Transitioning From IVIg to Efgartigimod PH20 SC — Completed
• Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls. — Completed
• A Study of Suboptimally Controlled Participants Previously Taking Oral or Infusion DMDs for RMS (MASTER-2) — Completed
• A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis — Running, not enrolling
• A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis — Completed
• PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706 — Stopped early
• A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's Disease — Running, not enrolling
• Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations — Running, not enrolling
• A Study of TAK-079 in People With Generalized Myasthenia Gravis — Completed
• Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis — Completed
• Acthar Gel for Multiple Sclerosis That Keeps Getting Better and Worse (RRMS) — Stopped early
• 12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine — Completed
• Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis — Completed
• Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS) — Completed
• A Study of a Drug to be Used in Addition With Another Drug to Treat Adults With Uncontrolled Partial-onset Seizures — Completed
• A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT) — Completed
• An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine — Completed
• Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease. — Stopped early
• Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine — Completed
• Registry of Amyloid Positive Patients for Alzheimer's Disease Drug Research Trials — Completed
• An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab — Completed
• Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two — Completed
• Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis — Completed
• Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs — Completed
• Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRx — Completed
• A Study to Evaluate Rituximab in Adults With Relapsing Remitting Multiple Sclerosis — Completed
• Determine Impact of Multiple NAb Tests on Treatment Compared to Usual Care of MS Patients on High-dose IFN Therapy — Completed
• Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis — Completed
• A Study to Evaluate the Effects of ONO-2506 Intravenous Infusion in Patients With Acute Ischemic Stroke — Stopped early
• Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis — Completed
• Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis — Completed